Abstract
This paper deals with other effects of obesity drugs than weight loss itself and weight loss related effects. The review does not pretend completeness. Rather will the effects — good and bad — be dealt with from examples putting the stress on experience from human studies of clinical relevance.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Andersen, P. H., Richelsen, B., Bak, J.,Schmitz,O.,Sorensen, N. S., Lavielle, R., & Pedersen, O. (1993). Influence ofshort-term dexfenfluramine therapy on glucose and lipid metabolism in obesenon-diabeticpatients.Acta Endocrinologica, 128, 251–258.
Andersen, T., Astrup, A., & Quaade,F. (1989). d-Fenfluramine reduces overweight but does not change food preferences. InternationalJournal of Obesity 13 (suppl 1) A136.
Andersson, B., Zimmermann. M. E., Hedner, T.,& Bjorntorp, P. (1991). Haemodymanic, metabolic and endocrine effectsof short-term dexfenfluramine treatment in young, obese women. EuropeanJournal of ClinicalPharmacology40, 249–254.
Astrup, A., Breum, L., Toubro, S., Hein, P., &Quaade,F. (1992), The effect and safety of an ephedrine/caffeinecoumpund compared to ephedrine, caffeine and placebo in obese subjects on anenergyrestricteddiet: A double blind trial. International Journal of Obesity. 16,269–277.
Astrup, A. Buemann, B., Christensen, N.J., Toubro, S., Thorbek, G., Victor, O. J., & Quaade, F. (1992). The effect of ephedrine/caffeine mixture on energy expenditure and bodycomposition in obese women. Metabolism. 41, 686–688.
Atanassoff, P. G., Weiss, B. M., Scmid,E. R., & Tornic, M. (1992). Pulmonary hypertension and dexfenfluramine. Lancet 339 436.
Bartig,K.(1993). Acute and chronic cardiovascular and behavioural effects of caffeine,aspirin and ephedrine.InternationalJournal of Obesity,17(suppl 1). S61–64.
Bengtsson, B-A,Eden, S., Lonn. L., Kvist. H., Stokland, A., Lindstedt, G., Bosaeus, I., Tolli,Sjostrom, L., &Isaksson,O. G. P. (1993). Journal of Clinical Endocrinology and Metabolism 76.309–317.
Blundell, J. E. (1992). Serotonin andthe biology of feeding. American Journal of Clinical Nutrition, 55, 155S–159S.
Bradley, M. J., Blum, N. J., &Scheib, R. K. (1974). Mazindol in obesity with known cardiac disease. Journalof InternationalMedical Research,2. 347–354.
Bray, G. A.(1992). Peptides affect the intake of specific nutrients and the sympatheticnervous system.AmericanJournal of Clinical Nutrition 55, 265S–271S.
Drent, M. L., & van der Veen, E. A.(1993) Lipase inhibition: A novel concept in the treatment of obesity. InternationalJournal of Obesity 17 241–244.
Foltin, R. W., Felly, T. H., &Fischman.M. W. (1990). The effect of d-amphetamine on food intake of humans living ina residential laboratory. Appetite 15, 33–46.
Goodall, E.,Feeney, S., McGuirk. J., &Silverstone, T. (1992). A comparison ofthe effects of d- and 1-feniluramineand d-amphetamine on energy and macronutrient intake in human subjects. Psychopharmacologv, 106,221–227
Hitzig. P. (1993).Combined dopamine and serotonin agonists: A synergistic approach to alcoholismandotheraddictive behaviors. Maryland Medical Journal. 42. 153–156.
Kopehnan. P. G.,Elliott, M. W., Smionds. A., Cramer. D , Ward. S.. & Wedzicha. J. A.(1992) Short-termuse of fluoxetine in asymptomatic obese subjects withsleep-related hypoventilation International Journal of Obesity 16, 825–830.
Krieger. D. R, Daly, P.A., Dulloo. A. G., Ransil B. J., Young, J. B., & Landsberg, L. (1990).Ephedrine.caffeineandaspum promote weight loss in obese subjects. Transactions of theAssociation of American Physicians 103,307–312.
Marcus. M. D., Wing. R. R., Ewing. L.Kern. E., McDermott. M., & Goodmg. W. (1990) A double-blind, placebo-controlledtrial of fluoxetine plus behavior modification in the treatment of obesebinge-eatersandnon-binge eaters. American Journal of Psychiatry 147, 876–881.
Marin, P., Holmang. S., Jonsson, L., Sjostrom, l., Kvist. H., Hom, G.,Lindstedt. G., & Bjorntorp. P. (1992). The effects of testosterone treatment onbody composition and metabolism in middle-aged men. InternationalJournal of Obesity16, 991–997.
Mathus-Vliegen. E. M. H., van de Voorde. K., Kok, A. M., & Res.A. M. A. (1992). Dexfenfluramine in the treatment of severe obesity: Aplacebo-controlled investigation of the effects on weight loss. cardiovascularrisk factors. food intake and eating behaviour. Journal of InternalMedicine 232 119– 127.
McTavish, D., & Heel. R. C. (1992). Dexfenfluramine. A review of its pharmacological properties and therapeuticpotential in obesity. Drugs 43, 713–733.
Morgan, J. P., & Funderburk. F. K.(1992). Phenylpropanolamine and blood pressure: A review of prospective studies. AmericanJournal of Clinical Nutrition 55, 206S–210S.
Naranjo, C. A., Kadlec, K. E., Sanhueza.P. Woodley-Remus. D., & Sellers. E. M. (1990). Fluoxetrne differentiallyalters alcohol intake and other consummatory behaviors in problem drinkers. Clinical Pharmacology andTherapeutics.47. 490–498.
Pasquali. R., Casimirri. F., Melchionda.N., Grossi, G. Bortoluzzi. L., Labate. A. M. M., Stefanini. C.,& Raitano. A. (1992).Effects of chronic administration of ephedrine during very low calorie diets onenergyexpenditure. protein metabolism and hormone levels inobese subjects, Clinical Science 82, 85–92.
Potter van Loon, B. J., Radder. J. K.,Frolich. M., Krans, H. M. J., Azinderman. A., H., & Meinders, A. E. (1992).Fluoxetrne increases insulin action in obese nondiabetic and in obesenon-insulin-dependentdiabeticindividuals. International Journal of Obesity 16,79–85.
Rasmussen, M. H., Frystyk. J., Andersen.T., Breum. L, Christiansen, J. S., & Hilsted, J. (1993). The impact of obesity, fatdistribution and energy restriction on insulin-like growth factor-1 (IGF-1).IGF -bindingprotein-3.insulin and growth hormone. Metabolism, in press.
Sax. L (1991). Yohimbine does not affectfat distribution in men. International Journal of Obesity, 15. 561– 565.
Skaggs. S. R. &Crist. D. M.(1991). Exogenous human growth hormone reduces body fat in obese women. Hormone Research, 35, 19–24.
Snyder, D. K., Underwood, L. E., &Clemmons, D. R. (1990). Anabolic effects of growth hormone in obese diet-restrictedsubjects are dose dependent. American Journal of Clinical Nutrition, 52,431–437.
Spring, B., Pingitore, R., & Kessler, K. (1992).Strategies to minimize weight gain after smoking cessation: Psychological andpharmacological intervention with specific reference to dexfenfluramine. InternationalJournal of Obesity, 16(suppl 3) S19–23.
Visser. M., Seidell. J. C.,Koppeschaar, H. P. F., & Smits, P. (1993). The effect of fluoxetine onbody weight, body composition and visceralfat accumulation. International Journal of Obesity. 17, 247–253.
Weintraub, M. (1992). Long-term weightcontrol study: Conclusions. Clinical Pharmacology and Therapeutics 51,642–646.
Wurtman,J. J. & Wurtman, R. J. (1984). d-Fenfluramine selectively decreasescarbohydreate but not protein intake in obese subjects. InternationalJournal of Obesity, 8(suppl 1), 79–84.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media New York
About this chapter
Cite this chapter
Andersen, T. (1995). Potential Side Costs and Side Benefits of Pharmacological Treatment of Obesity. In: Allison, D.B., Pi-Sunyer, F.X. (eds) Obesity Treatment. NATO ASI Series, vol 278. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1901-0_21
Download citation
DOI: https://doi.org/10.1007/978-1-4615-1901-0_21
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5776-6
Online ISBN: 978-1-4615-1901-0
eBook Packages: Springer Book Archive